# Efficacy of Tocilizumab on Patients With COVID-19

> **NCT04356937** · PHASE3 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 243 (actual)

## Conditions studied

- SARS-CoV 2

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04356937
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-20
- **Primary completion:** 2020-07-13
- **Final completion:** 2020-08-27
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2021-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04356937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04356937, "Efficacy of Tocilizumab on Patients With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04356937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*